Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Acute Lung Injury Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Acute Lung Injury Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Acute Lung Injury with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Pulmonary Edema of Mountaineers Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Pulmonary Edema of Mountaineers Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Pulmonary Edema of in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Pulmonary Edema Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Pulmonary Edema Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Pulmonary Edema with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Transfusion-Related Acute Lung Injury Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Transfusion-Related Acute Lung Injury Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Transfusion-Related Acute Lung in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Acute Chest Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Acute Chest Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Acute Chest Syndrome with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Embolism, Amniotic Fluid Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Embolism, Amniotic Fluid Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Embolism, Amniotic Fluid in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Embolism, Fat Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Embolism, Fat Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Embolism, Fat with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Embolism, Air Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Embolism, Air Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Embolism, Air with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Pulmonary Infarction Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Pulmonary Infarction Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Pulmonary Infarction with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Pulmonary Embolism Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Pulmonary Embolism Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Pulmonary Embolism with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Vasculitis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Vasculitis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Vasculitis with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Rapidly Progressive Glomerulonephritis With Pulmonary Hemorrhage Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Rapidly Progressive Glomerulonephritis With Pulmonary Hemorrhage Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Rapidly Progressive in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →